RecruitingNot ApplicableNCT03811171

Break Wave(TM) Extracorporeal Lithotripter First-in-Human Study

A Study of the SonoMotion Break Wave(TM) System for the Comminution of Urinary Tract Stones


Sponsor

SonoMotion

Enrollment

70 participants

Start Date

Aug 20, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

This is a prospective, open-label, multi-center, single-arm (non-randomized) study to assess the safety and effectiveness of breaking stones in the upper urinary tract using the SonoMotion Break Wave technology. Up to 30 subjects will be included. The procedure will be performed in a hospital surgical environment as an outpatient (without being admitted) or in a non-surgical environment such as a clinic or office procedure room. The procedure will be performed under varying levels of anesthesia ranging from no anesthesia to general anesthesia (fully asleep). Stones will be limited to ≤ 10 mm for lower pole stones and ≤ 20 mm everywhere else. Safety will be measured by the self-reported occurrences of adverse events, unplanned emergency department or clinic visits, and the need for further intervention. Fragmentation will be measured by self-reported stone passage and a comparison of computed tomography (CT) images before and after the procedure.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Break Wave extracorporeal lithotripsy for people with renal calculi and urinary calculi. The study is currently recruiting participants at 6 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEBreak Wave extracorporeal lithotripsy

The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an 85 mm aperture diameter therapy probe driven by a high voltage generator. The therapy probe has a cavity in the middle to accommodate coaxial alignment of an ultrasound imaging probe for treatment guidance.


Locations(6)

University of California San Diego Health

San Diego, California, United States

University of California, San Francisco

San Francisco, California, United States

University of Washington Medical Center

Seattle, Washington, United States

University of Alberta, Division of Urology

Edmonton, Alberta, Canada

Vancouver General Hospital Stone Centre

Vancouver, British Columbia, Canada

St. Michael's Unity Health Toronto

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03811171


Related Trials